Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Faes Farma, S.A. (FAE.MC)
Leioa, ES
Faes Farma, S.A. is a pharmaceutical enterprise dedicated to the research, development, manufacture, and distribution of both finished medicinal products and crucial raw materials. Its extensive operations span Spain and a multitude of international markets. The company's comprehensive product line encompasses prescription drugs, generic alternatives, over-the-counter (OTC) remedies, nutritional supplements, infant formula, and various other health-related items. Among its diverse offerings are Actimag (a magnesium pidolate), the anti-allergic Bilaxten, the anti-infective Bronquidiazina CR, Claversal for ulcerative colitis and Crohn's disease, the corticoid Dezacor, the anti-inflammatory Dolotren (also available as Dolotren Gel), Dynamogen (an anti-anorexic), Ferroprotina (an anti-anaemic), Hidroferol, Lipofen, Positon for dermatological conditions, strength-enhancing products such as Potenciator and Surmenalit, the laxative Pruina, the muscle relaxant and analgesic Robaxisal Compuesto, Trausan (a citicoline-based product), the venous vasoprotector Venosmil (and Venosmil Gel), and the anti-influenza medication Yendol. Furthermore, Faes Farma provides key active pharmaceutical ingredients, including Bilastine (an antihistamine molecule for allergic rhinitis, conjunctivitis, and urticaria), Calcifediol for bone metabolism, Deflazacort for treating osteoarticular diseases, Hidrosmin for venous insufficiency, and Mesalazine for digestive problems. The firm also engages in significant export activities. Founded in 1933, Faes Farma, S.A. is headquartered in Leioa, Spain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63% | -3.36% | -2.97% | -10.47% | +3.60% | -8.04% | +11.38% | +40.80% | +34.42% | +72.55% | +74.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+23.7% ★ Q1'26: +30.8% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-30.6% Q1'26: +8.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+6.9% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.9% Q1'26: +19.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+6.6% ★ Q1'26: +21.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+1.2% Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.03× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
204.72M
est: 205.61M (-0.4%)
|
228.64M
est: 228.84M (-0.1%)
|
274.58M
est: 279.29M (-1.7%)
|
324.31M
est: 330.18M (-1.8%)
|
357.40M
est: 367.83M (-2.8%)
|
380.24M
est: 392.23M (-3.1%)
|
398.56M
est: 406.72M (-2.0%)
|
438.75M
est: 439.33M (-0.1%)
|
451.17M
est: 493.75M (-8.6%)
|
493.65M
est: 497.53M (-0.8%)
|
610.46M
est: 589.58M (+3.5%)
|
702.95M
696.29M – 707.44M
+19.2% YoY
|
758.64M
744.81M – 767.97M
+7.9% YoY
|
850.20M
849.43M – 850.97M
+12.1% YoY
|
888.00M
879.59M – 893.67M
+4.4% YoY
|
| EBITDA |
45.40M
est: 55.55M (-18.3%)
|
52.24M
est: 61.82M (-15.5%)
|
58.39M
est: 75.45M (-22.6%)
|
72.47M
est: 89.20M (-18.8%)
|
87.22M
est: 99.37M (-12.2%)
|
100.26M
est: 105.97M (-5.4%)
|
110.84M
est: 109.88M (+0.9%)
|
121.35M
est: 118.69M (+2.2%)
|
122.93M
est: 123.82M (-0.7%)
|
128.33M
est: 124.77M (+2.9%)
|
101.80M
est: 147.85M (-31.2%)
|
176.28M
174.61M – 177.41M
+19.2% YoY
|
190.25M
186.78M – 192.59M
+7.9% YoY
|
213.21M
213.02M – 213.40M
+12.1% YoY
|
222.69M
220.58M – 224.11M
+4.4% YoY
|
| EBIT |
39.31M
est: 46.90M (-16.2%)
|
46.07M
est: 52.19M (-11.7%)
|
49.71M
est: 63.70M (-22.0%)
|
61.99M
est: 75.31M (-17.7%)
|
74.23M
est: 83.90M (-11.5%)
|
85.15M
est: 89.46M (-4.8%)
|
93.18M
est: 92.77M (+0.4%)
|
101.68M
est: 100.21M (+1.5%)
|
103.24M
est: 102.20M (+1.0%)
|
108.01M
est: 102.98M (+4.9%)
|
72.76M
est: 122.04M (-40.4%)
|
145.50M
144.12M – 146.43M
+19.2% YoY
|
157.03M
154.17M – 158.96M
+7.9% YoY
|
175.98M
175.82M – 176.14M
+12.1% YoY
|
183.80M
182.06M – 184.98M
+4.4% YoY
|
| Net Income |
30.36M
est: 38.60M (-21.3%)
|
36.59M
est: 44.91M (-18.5%)
|
42.22M
est: 49.16M (-14.1%)
|
51.59M
est: 60.94M (-15.3%)
|
63.96M
est: 73.82M (-13.4%)
|
72.55M
est: 78.43M (-7.5%)
|
82.39M
est: 83.80M (-1.7%)
|
89.50M
est: 89.64M (-0.2%)
|
91.90M
est: 97.26M (-5.5%)
|
111.36M
est: 92.50M (+20.4%)
|
79.63M
est: 76.51M (+4.1%)
|
87.00M
24.10M – 167.18M
+13.7% YoY
|
109.16M
106.04M – 112.28M
+25.5% YoY
|
126.00M
124.39M – 130.77M
+15.4% YoY
|
122.10M
120.60M – 123.11M
-3.1% YoY
|
| SGA |
27.23M
est: 36.68M (-25.7%)
|
25.97M
est: 40.82M (-36.4%)
|
33.29M
est: 49.82M (-33.2%)
|
38.77M
est: 58.89M (-34.2%)
|
48.30M
est: 65.61M (-26.4%)
|
41.19M
est: 69.96M (-41.1%)
|
49.32M
est: 72.55M (-32.0%)
|
115.89M
est: 78.36M (+47.9%)
|
57.37M
est: 101.02M (-43.2%)
|
132.55M
est: 101.79M (+30.2%)
|
146.19M
est: 120.63M (+21.2%)
|
143.82M
142.46M – 144.74M
+19.2% YoY
|
155.22M
152.39M – 157.13M
+7.9% YoY
|
173.95M
173.79M – 174.11M
+12.1% YoY
|
181.68M
179.96M – 182.84M
+4.4% YoY
|
| EPS |
0.12
est: 0.12 (-3.8%)
|
0.14
est: 0.15 (-3.6%)
|
0.15
est: 0.16 (-5.6%)
|
0.19
est: 0.20 (-3.6%)
|
0.23
est: 0.24 (-3.6%)
|
0.26
est: 0.25 (+2.6%)
|
0.28
est: 0.27 (+3.4%)
|
0.29
est: 0.29 (-0.8%)
|
0.30
est: 0.31 (-3.9%)
|
0.36
est: 0.30 (+21.6%)
|
0.26
est: 0.24 (+6.2%)
|
0.31
0.08 – 0.53
+24.8% YoY
|
0.35
0.34 – 0.36
+15.2% YoY
|
0.41
0.40 – 0.42
+15.8% YoY
|
0.39
0.39 – 0.39
-4.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-05 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-05-04 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree Europe SmallCap Dividend UCITS ETF WTES.DE | 0.38% | 351.5K | 0.38% |
| 2 | WisdomTree Europe SmallCap Dividend UCITS ETF Acc DFEA.L | 0.38% | 351.5K | 0.38% |
| 3 | WisdomTree Dynamic International SmallCap Equity ETF DDLS | 0.19% | 801.3K | 0.48% |
| 4 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR EGRW.L | 0.18% | 101.4K | 0.29% |
| 5 | WisdomTree Eurozone Quality Dividend Growth UCITS ETF - EUR Acc WTIM.DE | 0.18% | 101.4K | 0.29% |
| 6 | WisdomTree International SmallCap Dividend Fund DLS | 0.18% | 1.88M | 0.58% |
| 7 | WisdomTree International High Dividend Fund DTH | 0.07% | 422.9K | 0.58% |
| 8 | WisdomTree Europe Quality Dividend Growth Fund EUDG | 0.05% | 36.6K | 0.58% |
| 9 | Dimensional - International Small Cap ETF DFIS | 0.04% | 2.07M | 0.39% |
| 10 | Schwab Fundamental International Small Company Index ETF FNDC | 0.02% | 713.9K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eduardo Recoder de la Cuadra | CEO & Executive Director | 1M | male |
| Carlos Gutierrez Aguero | Chief People Officer | — | male |
| German Fernandez-Canodíaz | Chief Farm Faes Business Officer | — | male |
| Iker Etxezarreta Fraile | Chief Financial Officer | — | male |
| Isabel Najera | Chief Scientific & Medical Officer | — | female |
| Jaime Lopez | Global Head of IT | — | — |
| Jose Luis Diaz Capote | Chief International Business Officer | — | male |
| Maria Marin | Head of Investor Relations & External Communication | — | female |
| Mariana Soroa Zubiria | Chief GRC & Internal Audit Officer | — | female |
| Valentín Ruiz Unamunzaga | Chief Financial Officer | — | male |
| Alberto Fernández Fernández | Chief Marketing & Portfolio Strategy Officer | — | male |
| Xavier Arnaud | Chief Business Development Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for FAE.MC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
